BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lv R, Qiao W, Wu Z, Wang Y, Dai S, Liu Q, Zheng X. Tumor necrosis factor alpha blocking agents as treatment for ulcerative colitis intolerant or refractory to conventional medical therapy: a meta-analysis. PLoS One. 2014;9:e86692. [PMID: 24475168 DOI: 10.1371/journal.pone.0086692] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Iizuka M, Etou T, Sagara S. Efficacy of cytapheresis in patients with ulcerative colitis showing insufficient or lost response to biologic therapy. World J Gastroenterol 2022; 28(34): 4959-4972 [DOI: 10.3748/wjg.v28.i34.4959] [Reference Citation Analysis]
2 Rashidian A, Akbarzadeh D, Asgarpanah J, Dehpour A. Bunium persicum essential oil reduced acetic acid-induced rat colitis through suppression of NF-κB pathway. Avicenna J Phytomed 2021;11:505-14. [PMID: 34745922 DOI: 10.22038/AJP.2021.18037] [Reference Citation Analysis]
3 Yoshida A, Matsuoka K, Ueno F, Morizane T, Endo Y, Hibi T. Serum PR3-ANCA Is a Predictor of Primary Nonresponse to Anti-TNF-α Agents in Patients with Ulcerative Colitis. Inflamm Intest Dis 2021;6:117-22. [PMID: 34124183 DOI: 10.1159/000515361] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Liu X, Fan Y, Du L, Mei Z, Fu Y. In Silico and In Vivo Studies on the Mechanisms of Chinese Medicine Formula (Gegen Qinlian Decoction) in the Treatment of Ulcerative Colitis. Front Pharmacol 2021;12:665102. [PMID: 34177580 DOI: 10.3389/fphar.2021.665102] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
5 Iizuka M, Etou T, Shimodaira Y, Hatakeyama T, Sagara S. Cytapheresis re-induces high-rate steroid-free remission in patients with steroid-dependent and steroid-refractory ulcerative colitis. World J Gastroenterol 2021; 27(12): 1194-1212 [PMID: 33828394 DOI: 10.3748/wjg.v27.i12.1194] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Macaluso FS, Rodríguez-lago I. JAK Inhibition as a Therapeutic Strategy for Inflammatory Bowel Disease. CDM 2020;21:247-55. [DOI: 10.2174/1389200221666200310111409] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
7 Loftus EV Jr, Sands BE, Colombel JF, Dotan I, Khalid JM, Tudor D, Geransar P. Sustained Corticosteroid-Free Clinical Remission During Vedolizumab Maintenance Therapy in Patients with Ulcerative Colitis on Stable Concomitant Corticosteroids During Induction Therapy: A Post Hoc Analysis of GEMINI 1. Clin Exp Gastroenterol 2020;13:211-20. [PMID: 32606883 DOI: 10.2147/CEG.S248597] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Mei X, Zheng Q. Role of Cellular Biomolecules in Screening, Diagnosis and Treatment of Colorectal Cancer. CDM 2019;20:880-8. [DOI: 10.2174/1389200220666191018153428] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
9 Rashidian A, Rashki A, Abdollahi A, Haddadi N, Chamanara M, Mumtaz F, Dehpour AR. Dapsone reduced acetic acid-induced inflammatory response in rat colon tissue through inhibition of NF-kB signaling pathway. Immunopharmacology and Immunotoxicology 2019;41:607-13. [DOI: 10.1080/08923973.2019.1678635] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
10 Pantavou K, Yiallourou AI, Piovani D, Evripidou D, Danese S, Peyrin-Biroulet L, Bonovas S, Nikolopoulos GK. Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses. United European Gastroenterol J 2019;7:1285-303. [PMID: 31839954 DOI: 10.1177/2050640619883566] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
11 Kolehmainen S, Lepistö A, Färkkilä M. Impact of anti-TNF-alpha therapy on colectomy rate and indications for colectomy in ulcerative colitis: comparison of two patient cohorts from 2005 to 2007 and from 2014 to 2016. Scand J Gastroenterol 2019;54:707-11. [PMID: 31136207 DOI: 10.1080/00365521.2019.1620326] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
12 Simčič S, Berlec A, Stopinšek S, Štrukelj B, Orel R. Engineered and wild-type L. lactis promote anti-inflammatory cytokine signalling in inflammatory bowel disease patient's mucosa. World J Microbiol Biotechnol 2019;35:45. [PMID: 30810891 DOI: 10.1007/s11274-019-2615-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
13 Macaluso FS, Orlando A, Cottone M. Anti-interleukin-12 and anti-interleukin-23 agents in Crohn's disease. Expert Opin Biol Ther 2019;19:89-98. [PMID: 30571147 DOI: 10.1080/14712598.2019.1561850] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
14 Al-Dwairi A, Alqudah M, Al-Shboul O, Alfaqih M, Alomari D. Metformin exerts anti-inflammatory effects on mouse colon smooth muscle cells in vitro. Exp Ther Med 2018;16:985-92. [PMID: 30116349 DOI: 10.3892/etm.2018.6222] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
15 Wang F, Peng PL, Lin X, Chang Y, Liu J, Zhou R, Nie JY, Dong WG, Zhao Q, Li J. Regulatory role of NKG2D+ NK cells in intestinal lamina propria by secreting double-edged Th1 cytokines in ulcerative colitis. Oncotarget 2017;8:98945-52. [PMID: 29228739 DOI: 10.18632/oncotarget.22132] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
16 Rezayat SM, Dehpour AR, Motamed SM, Yazdanparast M, Chamanara M, Sahebgharani M, Rashidian A. Foeniculum vulgare essential oil ameliorates acetic acid-induced colitis in rats through the inhibition of NF-kB pathway. Inflammopharmacology 2018;26:851-9. [PMID: 29067571 DOI: 10.1007/s10787-017-0409-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 33] [Article Influence: 3.8] [Reference Citation Analysis]
17 Choi CH, Moon W, Kim YS, Kim ES, Lee BI, Jung Y, Yoon YS, Lee H, Park DI, Han DS; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Second Korean guidelines for the management of ulcerative colitis. Intest Res. 2017;15:7-37. [PMID: 28239313 DOI: 10.5217/ir.2017.15.1.7] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 7.4] [Reference Citation Analysis]
18 Choi CH, Moon W, Kim YS, Kim ES, Lee B, Jung Y, Yoon YS, Lee H, Park DI, Han DS; IBD Study Group of the Korean Association for the Study of the Intestinal Diseases. Second Korean Guideline for the Management of Ulcerative Colitis. Korean J Gastroenterol 2017;69:1. [DOI: 10.4166/kjg.2017.69.1.1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
19 Zhang ZM, Li W, Jiang XL. Efficacy and Safety of Adalimumab in Moderately to Severely Active Cases of Ulcerative Colitis: A Meta-Analysis of Published Placebo-Controlled Trials. Gut Liver. 2016;10:262-274. [PMID: 26780088 DOI: 10.5009/gnl15042] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
20 Shi HY, Chan FK, Tsang SW, Hui YT, Sze SF, Ching JY, Chung T, Iu CY, Lo FH, Shan EH, Li MK, Wu JC, Sung JJ, Ng SC. Factors associated with mucosal healing in patients with ulcerative colitis in clinical remission. Inflamm Bowel Dis 2015;21:840-6. [PMID: 25738375 DOI: 10.1097/MIB.0000000000000334] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
21 Huoponen S, Blom M. A Systematic Review of the Cost-Effectiveness of Biologics for the Treatment of Inflammatory Bowel Diseases. PLoS One 2015;10:e0145087. [PMID: 26675292 DOI: 10.1371/journal.pone.0145087] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
22 Lin L, Liu X, Wang D, Zheng C. Efficacy and safety of antiintegrin antibody for inflammatory bowel disease: a systematic review and meta-analysis. Medicine (Baltimore). 2015;94:e556. [PMID: 25761174 DOI: 10.1097/md.0000000000000556] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
23 Thorlund K, Druyts E, Toor K, Mills EJ. Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs. Expert Rev Gastroenterol Hepatol 2015;9:693-700. [PMID: 25763862 DOI: 10.1586/17474124.2015.1024657] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 5.4] [Reference Citation Analysis]
24 Bressler B, Marshall JK, Bernstein CN, Bitton A, Jones J, Leontiadis GI, Panaccione R, Steinhart AH, Tse F, Feagan B; Toronto Ulcerative Colitis Consensus Group. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology. 2015;148:1035-1058.e3. [PMID: 25747596 DOI: 10.1053/j.gastro.2015.03.001] [Cited by in Crossref: 211] [Cited by in F6Publishing: 220] [Article Influence: 30.1] [Reference Citation Analysis]
25 Lopez A, Ford AC, Colombel JF, Reinisch W, Sandborn WJ, Peyrin-Biroulet L. Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trials. Dig Liver Dis. 2015;47:356-364. [PMID: 25661014 DOI: 10.1016/j.dld.2015.01.148] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
26 Lang M, Gasche C. Chemoprevention of colorectal cancer. Dig Dis 2015;33:58-67. [PMID: 25531498 DOI: 10.1159/000366037] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
27 Lv Y, Xu X, Zhang B, Zhou G, Li H, Du C, Han H, Wang H. Endometrial regenerative cells as a novel cell therapy attenuate experimental colitis in mice. J Transl Med. 2014;12:344. [PMID: 25475342 DOI: 10.1186/s12967-014-0344-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 3.5] [Reference Citation Analysis]
28 Odes S, Greenberg D. A medicoeconomic review of early intervention with biologic agents in the treatment of inflammatory bowel diseases. Clinicoecon Outcomes Res 2014;6:431-43. [PMID: 25336980 DOI: 10.2147/CEOR.S39212] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
29 Chae HB, Jung YS, Park DI, Lee CK, Huh KC, Shin JE, Kim JH, Kim YS, Jung Y, Jung SA, Song HJ, Jang HJ, Hong SN, Kim YH. [Differences in the prognosis according to the periods of diagnosis in ulcerative colitis]. Korean J Gastroenterol 2014;64:93-7. [PMID: 25168051 DOI: 10.4166/kjg.2014.64.2.93] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
30 Tursi A, Elisei W, Picchio M, Penna A, Lecca PG, Forti G, Giorgetti G, Faggiani R, Zampaletta C, Pelecca G. Managing ambulatory ulcerative colitis patients with infliximab: a long term follow-up study in primary gastroenterology centers. Eur J Intern Med. 2014;25:757-761. [PMID: 25086677 DOI: 10.1016/j.ejim.2014.07.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
31 Xu H, Zhang Y, Lei Y, Gao X, Zhai H, Lin N, Tang S, Liang R, Ma Y, Li D, Zhang Y, Zhu G, Yang H, Huang L. A systems biology-based approach to uncovering the molecular mechanisms underlying the effects of dragon's blood tablet in colitis, involving the integration of chemical analysis, ADME prediction, and network pharmacology. PLoS One 2014;9:e101432. [PMID: 25068885 DOI: 10.1371/journal.pone.0101432] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
32 Aceituno M, Zabana Y, Esteve M. [Treatment of severe ulcerative colitis flares]. Gastroenterol Hepatol 2014;37:471-9. [PMID: 25015428 DOI: 10.1016/j.gastrohep.2014.05.005] [Reference Citation Analysis]